These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 9690573)
1. Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma. Weinstein SF; Pearlman DS; Bronsky EA; Byrne A; Arledge T; Liddle R; Stahl E Ann Allergy Asthma Immunol; 1998 Jul; 81(1):51-8. PubMed ID: 9690573 [TBL] [Abstract][Full Text] [Related]
2. Comparison of powder and aerosol formulations of salmeterol in the treatment of asthma. Wolfe J; Kreitzer S; Chervinsky P; Lawrence M; Wang Y; Reilly D; Davis S; Stahl E Ann Allergy Asthma Immunol; 2000 Mar; 84(3):334-40. PubMed ID: 10752919 [TBL] [Abstract][Full Text] [Related]
3. Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. Blake K; Pearlman DS; Scott C; Wang Y; Stahl E; Arledge T Ann Allergy Asthma Immunol; 1999 Feb; 82(2):205-11. PubMed ID: 10071526 [TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma. Busse WW; Casale TB; Murray JJ; Petrocella V; Cox F; Rickard K Am J Manag Care; 1998 Nov; 4(11):1579-87. PubMed ID: 10338904 [TBL] [Abstract][Full Text] [Related]
5. Salmeterol xinafoate in children on high dose inhaled steroids. Russell G; Williams DA; Weller P; Price JF Ann Allergy Asthma Immunol; 1995 Nov; 75(5):423-8. PubMed ID: 7583864 [TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma. Wenzel SE; Lumry W; Manning M; Kalberg C; Cox F; Emmett A; Rickard K Ann Allergy Asthma Immunol; 1998 Jun; 80(6):463-70. PubMed ID: 9647268 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study. Maspero J; Guerra F; Cuevas F; Gutierrez JP; Soto-Ramos M; Anderton S; Mechali D; Chan R; Pedersen S Clin Ther; 2008 Aug; 30(8):1492-504. PubMed ID: 18803991 [TBL] [Abstract][Full Text] [Related]
8. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. Simons FE N Engl J Med; 1997 Dec; 337(23):1659-65. PubMed ID: 9385125 [TBL] [Abstract][Full Text] [Related]
9. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study. Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690 [TBL] [Abstract][Full Text] [Related]
10. A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma. Nathan RA; Pinnas JL; Schwartz HJ; Grossman J; Yancey SW; Emmett AH; Rickard KA Ann Allergy Asthma Immunol; 1999 Jun; 82(6):521-9. PubMed ID: 10400478 [TBL] [Abstract][Full Text] [Related]
11. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853 [TBL] [Abstract][Full Text] [Related]
12. Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma. Galant SP; van Bavel J; Finn A; Gross G; Pleskow W; Brown A; Hamedani AG; Harding SM Ann Allergy Asthma Immunol; 1999 Mar; 82(3):273-80. PubMed ID: 10094218 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma. LaForce CF; Pearlman DS; Ruff ME; Silvers WS; Weinstein SW; Clements DS; Brown A; Duke S; Harding SM; House KW Ann Allergy Asthma Immunol; 2000 Nov; 85(5):407-15. PubMed ID: 11101186 [TBL] [Abstract][Full Text] [Related]
14. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. Pearlman DS; Chervinsky P; LaForce C; Seltzer JM; Southern DL; Kemp JP; Dockhorn RJ; Grossman J; Liddle RF; Yancey SW N Engl J Med; 1992 Nov; 327(20):1420-5. PubMed ID: 1357554 [TBL] [Abstract][Full Text] [Related]
15. Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023). Baumgarten C; Geldszus R; Behre U; Peslis N; Trautmann M; Eur J Med Res; 2002 Jan; 7(1):1-7. PubMed ID: 11827834 [TBL] [Abstract][Full Text] [Related]
16. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371 [TBL] [Abstract][Full Text] [Related]
17. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216 [TBL] [Abstract][Full Text] [Related]
18. Salmeterol compared with current therapies in chronic asthma. Adinoff AD; Schwartz HJ; Rickard KA; Yancey SW; Swearingen BE J Fam Pract; 1998 Oct; 47(4):278-84. PubMed ID: 9789513 [TBL] [Abstract][Full Text] [Related]
19. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. Bateman ED; Kornmann O; Schmidt P; Pivovarova A; Engel M; Fabbri LM J Allergy Clin Immunol; 2011 Aug; 128(2):315-22. PubMed ID: 21807250 [TBL] [Abstract][Full Text] [Related]